CALR‐mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27265
Abstract: A low allele burden (i.e., read more here.
Keywords: calr mutated; allele burden; essential thrombocythemia; low allele ... See more keywords
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27400
Abstract: The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the… read more here.
Keywords: vera essential; essential thrombocythemia; reduction; impact ... See more keywords
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27418
Abstract: Patients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short‐term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice‐daily aspirin… read more here.
Keywords: low dose; aspirin; daily low; twice daily ... See more keywords
Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Laboratory Analysis"
DOI: 10.1002/jcla.24522
Abstract: The genetic investigation of essential thrombocythemia(ET) has highlighted the presence of driver mutations in ET. Janus kinase JAK2V617F and calreticulin(CALR) mutations are the most frequent driver mutations and have significantly improved the molecular diagnosis of… read more here.
Keywords: essential thrombocythemia; calreticulin; v617f calreticulin; hematological relevance ... See more keywords
Late‐Onset Chorea in JAK2‐Associated Essential Thrombocythemia
Sign Up to like & getrecommendations! Published in 2021 at "Movement Disorders Clinical Practice"
DOI: 10.1002/mdc3.13105
Abstract: Somatic mutations in JAK2 are associated with chronic myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis (PMF). The most common variant, Val617Phe (JAK2), accounts for >95% of polycythemia vera and 50%–60% of… read more here.
Keywords: late onset; jak2 associated; polycythemia vera; essential thrombocythemia ... See more keywords
Chorea Associated with JAK2V617F ‐Positive Essential Thrombocythemia
Sign Up to like & getrecommendations! Published in 2022 at "Movement Disorders Clinical Practice"
DOI: 10.1002/mdc3.13567
Abstract: It is with great interest that we read the article by Kutty and colleagues on chorea in patients with JAK2-mutated essential thrombocythemia (ET). As pointed out by the authors, the occurrence of chorea has rarely… read more here.
Keywords: essential thrombocythemia; chorea associated; case; chorea ... See more keywords
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-05665-4
Abstract: Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they… read more here.
Keywords: treatment; trial; ropeginterferon alfa; patients limited ... See more keywords
Proinflammatory and prothrombotic conditions in JAK2V617F-positive MPN: a case of Lemierre’s syndrome in essential thrombocythemia
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06234-z
Abstract: Lemierre’s syndrome (LS) represents a rare yet potentially life-threatening systemic infection, characterized by thrombophlebitis of the internal jugular vein and abscess formation in distant organs. It typically follows episodes of tonsillitis or other infections of… read more here.
Keywords: lemierre syndrome; jak2v617f positive; proinflammatory prothrombotic; mpn ... See more keywords
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03929-9
Abstract: Fedratinib (SAR302503, TG101348) is an orally administered Janus kinase (JAK) 2-selective inhibitor that is being developed for the treatment of patients with myelofibrosis (MF). The objectives of this analysis were to develop a population pharmacokinetic… read more here.
Keywords: fedratinib; polycythemia vera; vera essential; patients myelofibrosis ... See more keywords
Austrian recommendations for the management of essential thrombocythemia
Sign Up to like & getrecommendations! Published in 2020 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-020-01761-3
Abstract: According to the World Health Organization (WHO) classification, essential (primary) thrombocythemia (ET) is one of several Bcr-Abl negative chronic myeloproliferative neoplasms (MPN). The classical term MPN covers the subcategories of MPN: ET, polycythemia vera (PV),… read more here.
Keywords: recommendations management; essential thrombocythemia; management essential; thrombocythemia ... See more keywords
Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-017-1490-4
Abstract: For the patients with essential thrombocythemia (ET), systemic thrombosis presents as one of the most dangerous complications. It’s been widely accepted that acute coronary syndrome (ACS) is a kind of thrombotic diseases. However, there are… read more here.
Keywords: treatment; acute coronary; coronary syndrome; essential thrombocythemia ... See more keywords